These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8255925)

  • 1. Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital.
    Dall V; Orntoft U; Schmidt A; Nordholm L
    Pharmacol Biochem Behav; 1993 Sep; 46(1):73-6. PubMed ID: 8255925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMPA receptor competitive antagonism reduces halothane MAC in rats.
    McFarlane C; Warner DS; Todd MM; Nordholm L
    Anesthesiology; 1992 Dec; 77(6):1165-70. PubMed ID: 1334638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticonvulsant, anxiolytic and discriminative effects of the AMPA antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX).
    Swedberg MD; Jacobsen P; Honoré T
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1113-21. PubMed ID: 7562477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed antagonism of AMPA/kainate receptors reduces long-term functional deficits resulting from spinal cord trauma.
    Wrathall JR; Teng YD; Marriott R
    Exp Neurol; 1997 Jun; 145(2 Pt 1):565-73. PubMed ID: 9217092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2,3-dione) in mice, rats, and dogs. Interactions with probenecid.
    Dalgaard L; Hjortkjaer RK; Regnier B; Nordholm L
    Drug Metab Dispos; 1994; 22(2):289-93. PubMed ID: 7912178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some behavioral effects of CNQX AND NBQX, AMPA receptor antagonists.
    Maj J; Rogóz Z; Skuza G; Jaros T
    Pol J Pharmacol; 1995; 47(4):269-77. PubMed ID: 8616504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy.
    Namba T; Morimoto K; Sato K; Yamada N; Kuroda S
    Brain Res; 1994 Feb; 638(1-2):36-44. PubMed ID: 8199874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic uptake and biliary excretion of the neuroprotectant 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo-(F)-quinoxaline in rat liver. Involvement of an organic anion transport system.
    Hansen KT
    Biochem Pharmacol; 1995 Feb; 49(4):489-93. PubMed ID: 7872954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous NBQX inhibits spontaneously occurring sympathetic nerve activity and reduces blood pressure in cats.
    Chen K; Hernandez YM; Dretchen KL; Gillis RA
    Eur J Pharmacol; 1994 Feb; 252(2):155-60. PubMed ID: 8157056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NBQX, a selective antagonist of the AMPA receptor, affects neither field potentials nor long-term potentiation in vivo.
    Sato K; Morimoto K; Yamada N; Kuroda S; Hayabara T
    Brain Res; 1995 Jun; 683(2):279-82. PubMed ID: 7552367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPA receptor antagonists and local cerebral glucose utilization in the rat.
    Browne SE; McCulloch J
    Brain Res; 1994 Mar; 641(1):10-20. PubMed ID: 8019834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the AMPA-receptor antagonist, NBQX, on neuron loss in dentate hilus of the hippocampal formation after 8, 10, or 12 min of cerebral ischemia in the rat.
    Hu P; Diemer NH; Bruhn T; Johansen FF
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):147-52. PubMed ID: 9040493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline on methamphetamine- and cocaine-induced behavioral sensitization.
    Akiyama K; Ujike H; Sakai K; Shimizu Y; Kodama M; Kuroda S
    Pharmacol Biochem Behav; 1998 Dec; 61(4):419-26. PubMed ID: 9802837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model.
    Gill R; Nordholm L; Lodge D
    Brain Res; 1992 May; 580(1-2):35-43. PubMed ID: 1504814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of intravenous NBQX and GYKI 53655 as AMPA antagonists in the rat spinal cord.
    Chizh BA; Cumberbatch MJ; Headley PM
    Br J Pharmacol; 1994 Jul; 112(3):843-6. PubMed ID: 7522860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of YM90K, a selective and potent antagonist of AMPA receptors, in rat cortical mRNA-injected Xenopus oocytes.
    Okada M; Kohara A; Yamaguchi T
    Eur J Pharmacol; 1996 Aug; 309(3):299-306. PubMed ID: 8874154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of MK-801-induced breathing impairment by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline.
    McManigle JE; Taveira DaSilva AM; Dretchen KL; Gillis RA
    Eur J Pharmacol; 1994 Jan; 252(1):11-7. PubMed ID: 8149990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AMPA receptor antagonist NBQX exerts antidystonic effects in an animal model of idiopathic dystonia.
    Richter A; Löscher W; Löschmann PA
    Eur J Pharmacol; 1993 Feb; 231(2):287-91. PubMed ID: 8384114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competitive inhibition by NBQX of kainate/AMPA receptor currents and excitatory synaptic potentials: importance of 6-nitro substitution.
    Randle JC; Guet T; Cordi A; Lepagnol JM
    Eur J Pharmacol; 1992 May; 215(2-3):237-44. PubMed ID: 1382998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of stress-induced adrenocorticotropin and prolactin secretion mediating hypophysiotropic factors by antagonist of AMPA type glutamate receptor.
    Kusakawa S; Tohei A; Jaroenporn S; Watanabe G; Taya K
    J Reprod Dev; 2007 Jun; 53(3):545-54. PubMed ID: 17272925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.